Home >Archive

Volume: 3, Issue: 5, Sep-Oct, 2015
DOI: 10.7324/JABB.2015.3508

Research Article

A Chromatography based interaction analysis of two important biomolecules: neurotoxic Amyloid beta oligomers and human blood plasma proteins

Anuj Kumer Das1 2

  Author Affiliations


A Size exclusion Chromatographic analysis was carried out to study the co-elution pattern as well as the molecular interaction between neurotoxic Amyloid beta oligomers and human blood plasma proteins. Four different types of Chromatographic columns like Sephacryl S-100 HR, Superose 12HR 10/30, Superdex 75 HR 10/300 and Superdex 200 HR10/300 used for analysis and among these columns, Superdex 200 HR 10/300 shown to be the most convenient column with better resolution where 20 mM sodium phosphate, pH 7.4; 150 mM sodium chloride proved as best working buffer at 0.5 ml/min flow rate. Co-elution study of mixture of amyloid β oligomers and human plasma serum showed weak molecular interactions with blood plasma proteins but no strong interaction could be observed.


Size exclusion chromatography, molecular interaction, Amyloid beta oligomers, human blood plasma proteins.

Citation: Anuj Kumer Das. A Chromatography based interaction analysis of two important biomolecules: neurotoxic Amyloid beta oligomers and human blood plasma proteins. J App Biol Biotech. 2015; 3 (05): 040-043. DOI: 10.7324/JABB.2015.3508

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.


1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-356.

2. Cleary JP1, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005; 8: 79-84.

3. Glenner GG, Wong CW. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120:885-890.

4. Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid \ß-protein. J Alzheimers Dis. 2001; 3:75-80.

5. Walsh DM, Selkoe DJ. A\ß oligomers - a decade of discovery. J Neurochem. 2007; 101:1172-1184.

6. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid \ß-protein assembly and Alzheimer disease. J Biol Chem. 2009; 284:4749-4753

7. Ondrejcak T, Klyubin I, Hu N-W, Barry AE, Cullen WK, Rowan MJ. Alzheimer’s disease amyloid \ß-protein and synaptic function. Neuromol Med. 2010; 12:13-26.

8. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of A\ß oligomers. FEBS J. 2010; 277:1348-1358.

9. Ferreira ST, Klein WL. The A\ß oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem. 2011; 96:529-543.

10. Benilova I, Karran E, De Strooper B. The toxic A\ß oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012; 15:349-357.

11. Hayden EY, Teplow DB. Amyloid \ß-protein oligomers and Alzheimer’s disease. Alzheimers Res Ther. 2013; 5:60.

12. Roth M, Tomlinson BE, Blessed G. Correlation between scores for dementia and counts of ‘senile plaques’ in cerebral grey matter of elderly subjects. Nature. 1966; 209:109-110.

13. BurtisCA, and Ashwood ER. Tietz Fundamentals of Clinical Chemistry, 5th edition; W.B. Saunders company, Philadeslphia,PA. 2001.

14. Turner MW and Hulme B. The Plasma Proteins: An Introduction. Pitman Medical & Scientific Publishing Co. Ltd., London.1970.

15. Schrader M and Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 2001; 19: S55-S60.

16. Kennedy S. Proteomic profiling from human samples: the body fluid alternative; Toxicol. Lett. 2001; 120: 379-884.

17. Wrotnowski C. The future of plasma proteins. Genet. Eng. News. 1998;18: 14.

18. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH; Smith RD, Springer DL, Pounds JG. Toward a human blood serum proteome: analysis by multi-dimensional separation coupled with mass spectrometry. Mol Cell Proteomics. 2002; 1: 947-955.

19. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo. M Smith. C, Kupchak P, Kireeva I, Ingratta L, Jackowski G. Mining biomarkers in human sera using proteomic tools. Proteomics. 2004; 4: 244-256.

20. Anderson NL, Anderson NG. The human plasma proteome: history, character and diagnostic prospects. Mol Cell Proteomics. 2002; 1: 845-867.

21. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, Su Q, McGrath AM, Estock MA, Parmar PP, Zhao M, Huang ST, Zhou J, Wang F, Esquer-Blasco R, Anderson NL, Taylor J, Steiner S. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics.2003; 3: 1345-1364.

22. Macao B, Hoyer W, Sandberg A, Brorsson A-C, Dobson CM, Hard T. Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. BMC Biotechnol. 2008; 8:82.

23. Merril CR. Silver staining of proteins and DNA. Nature. 1990; 343 (6260): 779-80

Article Metrics

Similar Articles